306 related articles for article (PubMed ID: 18412969)
21. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
[TBL] [Abstract][Full Text] [Related]
22. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
Behboudi S; Moore A; Gilbert SC; Nicoll CL; Hill AV
Vaccine; 2004 Oct; 22(31-32):4326-31. PubMed ID: 15474725
[TBL] [Abstract][Full Text] [Related]
24. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
25. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
Drexler I; Antunes E; Schmitz M; Wölfel T; Huber C; Erfle V; Rieber P; Theobald M; Sutter G
Cancer Res; 1999 Oct; 59(19):4955-63. PubMed ID: 10519409
[TBL] [Abstract][Full Text] [Related]
26. Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells.
Flechsig C; Suezer Y; Kapp M; Tan SM; Löffler J; Sutter G; Einsele H; Grigoleit GU
Cytotherapy; 2011 Jul; 13(6):739-52. PubMed ID: 21250864
[TBL] [Abstract][Full Text] [Related]
27. Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.
Wolferstätter M; Schweneker M; Späth M; Lukassen S; Klingenberg M; Brinkmann K; Wielert U; Lauterbach H; Hochrein H; Chaplin P; Suter M; Hausmann J
J Virol; 2014 Dec; 88(24):14396-411. PubMed ID: 25297997
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-1β receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1β activity produced in various virus-infected antigen-presenting cells.
Zimmerling S; Waibler Z; Resch T; Sutter G; Schwantes A
Virol J; 2013 Jan; 10():34. PubMed ID: 23356675
[TBL] [Abstract][Full Text] [Related]
29. The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments
de Freitas LFD; Oliveira RP; Miranda MCG; Rocha RP; Barbosa-Stancioli EF; Faria AMC; da Fonseca FG
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567985
[TBL] [Abstract][Full Text] [Related]
30. CD70 encoded by modified vaccinia virus Ankara enhances CD8 T-cell-dependent protective immunity in MHC class II-deficient mice.
Bathke B; Pätzold J; Kassub R; Giessel R; Lämmermann K; Hinterberger M; Brinkmann K; Chaplin P; Suter M; Hochrein H; Lauterbach H
Immunology; 2018 Jun; 154(2):285-297. PubMed ID: 29281850
[TBL] [Abstract][Full Text] [Related]
31. Human cytomegalovirus pp65- and immediate early 1 antigen-specific HLA class I-restricted cytotoxic T cell responses induced by cross-presentation of viral antigens.
Tabi Z; Moutaftsi M; Borysiewicz LK
J Immunol; 2001 May; 166(9):5695-703. PubMed ID: 11313411
[TBL] [Abstract][Full Text] [Related]
32. The purinergic receptor P2X7 as a modulator of viral vector-mediated antigen cross-presentation.
Longo Y; Mascaraque SM; Andreacchio G; Werner J; Katahira I; De Marchi E; Pegoraro A; Lebbink RJ; Köhrer K; Petzsch P; Tao R; Di Virgilio F; Adinolfi E; Drexler I
Front Immunol; 2024; 15():1360140. PubMed ID: 38711513
[TBL] [Abstract][Full Text] [Related]
33. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2.
Trevor KT; Hersh EM; Brailey J; Balloul JM; Acres B
Cancer Immunol Immunother; 2001 Oct; 50(8):397-407. PubMed ID: 11726134
[TBL] [Abstract][Full Text] [Related]
34. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
35. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
36. Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells.
Larsson M; Fonteneau JF; Somersan S; Sanders C; Bickham K; Thomas EK; Mahnke K; Bhardwaj N
Eur J Immunol; 2001 Dec; 31(12):3432-42. PubMed ID: 11745362
[TBL] [Abstract][Full Text] [Related]
37. Modulation of Cell Surface Receptor Expression by Modified Vaccinia Virus Ankara in Leukocytes of Healthy and HIV-Infected Individuals.
Leite Pereira A; Jouhault Q; Marcos Lopez E; Cosma A; Lambotte O; Le Grand R; Lehmann MH; Tchitchek N
Front Immunol; 2020; 11():2096. PubMed ID: 33013882
[TBL] [Abstract][Full Text] [Related]
38. Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
Tan WG; Zubkova I; Kachko A; Wells F; Adler H; Sutter G; Major ME
PLoS One; 2017; 12(7):e0181578. PubMed ID: 28732046
[TBL] [Abstract][Full Text] [Related]
39. Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus.
Subklewe M; Chahroudi A; Schmaljohn A; Kurilla MG; Bhardwaj N; Steinman RM
Blood; 1999 Aug; 94(4):1372-81. PubMed ID: 10438725
[TBL] [Abstract][Full Text] [Related]
40. Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors.
Tenesaca S; Vasquez M; Alvarez M; Otano I; Fernandez-Sendin M; Di Trani CA; Ardaiz N; Gomar C; Bella A; Aranda F; Medina-Echeverz J; Melero I; Berraondo P
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
